5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Hand-Foot O
Syndrome O
may O
occur O
. O

Dose O
modification O
or O
discontinuation O
may O
be O
required O
( O
5.3 O
) O
* O
Embryofetal O
Toxicity O
: O
Can O
cause O
fetal O
harm O
. O

Advise O
of O
potential O
risk O
to O
a O
fetus O
. O

Use O
effective O
contraception O
( O
5.5 O
, O
8.1 O
, O
8.3 O
) O
5.1 O
Cardiomyopathy O
Doxorubicin O
HCl O
can O
result O
in O
myocardial B-OSE_Labeled_AE
damage I-OSE_Labeled_AE
, O
including O
acute B-OSE_Labeled_AE
left I-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
. O

The O
risk O
of O
cardiomyopathy B-OSE_Labeled_AE
with O
doxorubicin O
HCl O
is O
generally O
proportional O
to O
the O
cumulative O
exposure O
. O

The O
relationship O
between O
cumulative O
DOXIL O
dose O
and O
the O
risk O
of O
cardiac B-NonOSE_AE
toxicity I-NonOSE_AE
has O
not O
been O
determined O
. O

In O
a O
clinical O
study O
in O
250 O
patients O
with O
advanced O
cancer B-Not_AE_Candidate
who O
were O
treated O
with O
DOXIL O
, O
the O
risk O
of O
cardiotoxicity B-OSE_Labeled_AE
was O
11 O
% O
when O
the O
cumulative O
anthracycline O
dose O
was O
between O
450-550 O
mg/m O
2 O
. O

Cardiotoxicity B-NonOSE_AE
was O
defined O
as O
> B-NonOSE_AE
2 I-NonOSE_AE
0 I-NonOSE_AE
% I-NonOSE_AE
decrease I-NonOSE_AE
in I-NonOSE_AE
resting I-NonOSE_AE
left I-NonOSE_AE
ventricular I-NonOSE_AE
ejection I-NonOSE_AE
fraction I-NonOSE_AE
( I-NonOSE_AE
LVEF I-NonOSE_AE
) O
from O
baseline O
where O
LVEF O
remained O
in O
the O
normal O
range O
or O
a O
> O
10 O
% O
decrease B-NonOSE_AE
in I-NonOSE_AE
LVEF I-NonOSE_AE
from O
baseline O
where O
LVEF O
was O
less O
than O
the O
institutional O
lower O
limit O
of O
normal O
. O

Two O
percent O
of O
patients O
developed O
signs O
and O
symptoms O
of O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
without O
documented O
evidence O
of O
cardiotoxicity B-NonOSE_AE
. O

Assess O
left O
ventricular O
cardiac O
function O
( O
e.g O
. O

MUGA O
or O
echocardiogram O
) O
prior O
to O
initiation O
of O
DOXIL O
, O
during O
treatment O
to O
detect O
acute O
changes O
, O
and O
after O
treatment O
to O
detect O
delayed O
cardiotoxicity B-NonOSE_AE
. O

Administer O
DOXIL O
to O
patients O
with O
a O
history O
of O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
only O
when O
the O
potential O
benefit O
of O
treatment O
outweighs O
the O
risk O
. O

5.2 O
Infusion-Related O
Reactions O
Serious O
and O
sometimes O
life-threatening O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
characterized O
by O
one O
or O
more O
of O
the O
following O
symptoms O
can O
occur O
with O
DOXIL O
: O
flushing B-NonOSE_AE
, O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
, O
facial B-NonOSE_AE
swelling I-NonOSE_AE
, O
headache B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
chest B-NonOSE_AE
pain I-NonOSE_AE
, O
back B-NonOSE_AE
pain I-NonOSE_AE
, O
tightness B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
chest O
and O
throat I-NonOSE_AE
, O
fever B-NonOSE_AE
, O
tachycardia B-NonOSE_AE
, O
pruritus B-NonOSE_AE
, O
rash B-NonOSE_AE
, O
cyanosis B-NonOSE_AE
, O
syncope B-NonOSE_AE
, O
bronchospasm B-NonOSE_AE
, O
asthma B-NonOSE_AE
, O
apnea B-NonOSE_AE
, O
and O
hypotension B-NonOSE_AE
. O

The O
majority O
of O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
events I-OSE_Labeled_AE
occurred O
during O
the O
first O
infusion O
. O

Of O
239 O
patients O
with O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
treated O
with O
DOXIL O
in O
Trial O
4 O
, O
7 O
% O
of O
patients O
experienced O
acute O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
resulting O
in O
dose O
interruption O
. O

All O
occurred O
during O
cycle O
1 O
and O
none O
during O
subsequent O
cycles O
. O

Across O
multiple O
studies O
of O
DOXIL O
monotherapy O
including O
this O
and O
other O
studies O
enrolling O
760 O
patients O
with O
various O
solid B-Not_AE_Candidate
tumors I-Not_AE_Candidate
, O
11 O
% O
of O
patients O
had O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Ensure O
that O
medications O
to O
treat O
infusion B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
reactions I-NonOSE_AE
and O
cardiopulmonary O
resuscitative O
equipment O
are O
available O
for O
immediate O
use O
prior O
to O
initiation O
of O
DOXIL O
. O

Initiate O
DOXIL O
infusions O
at O
a O
rate O
of O
1 O
mg/min O
and O
increase O
rate O
as O
tolerated O
[ O
see O
Dosage O
and O
Administration O
( O
2.6 O
) O
] O
. O

In O
the O
event O
of O
an O
infusion B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
reaction I-NonOSE_AE
, O
temporarily O
stop O
the O
drug O
until O
resolution O
then O
resume O
at O
a O
reduced O
infusion O
rate O
. O

Discontinue O
DOXIL O
infusion O
for O
serious O
or O
life-threatening O
infusion B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
reactions I-NonOSE_AE
. O

5.3 O
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Foot I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HFS I-OSE_Labeled_AE
) O
In O
Trial O
4 O
, O
the O
incidence O
of O
HFS B-OSE_Labeled_AE
was O
51 O
% O
of O
patients O
in O
the O
DOXIL O
arm O
and O
0.9 O
% O
of O
patients O
in O
the O
topotecan O
arm O
, O
including O
24 O
% O
Grade O
3 O
or O
4 O
cases O
of O
HFS B-OSE_Labeled_AE
in O
DOXIL-treated O
patients O
and O
no O
Grade O
3 O
or O
4 O
cases O
in O
topotecan-treated O
patients O
. O

HFS B-OSE_Labeled_AE
or O
other O
skin B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
required O
discontinuation O
of O
DOXIL O
in O
4.2 O
% O
of O
patients O
. O

HFS B-OSE_Labeled_AE
was O
generally O
observed O
after O
2 O
or O
3 O
cycles O
of O
treatment O
but O
may O
occur O
earlier O
. O

Delay O
DOXIL O
for O
the O
first O
episode O
of O
Grade O
2 O
or O
greater O
HFS B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.5 O
) O
] O
. O

Discontinue O
DOXIL O
if O
HFS B-NonOSE_AE
is O
severe O
and O
debilitating O
. O

5.4 O
Secondary O
Oral O
Neoplasms O
Secondary B-OSE_Labeled_AE
oral I-OSE_Labeled_AE
cancers I-OSE_Labeled_AE
, O
primarily O
squamous B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
, O
have O
been O
reported O
from O
post-marketing O
experience O
in O
patients O
with O
long-term O
( O
more O
than O
one O
year O
) O
exposure O
to O
DOXIL O
. O

These O
malignancies B-OSE_Labeled_AE
were O
diagnosed O
both O
during O
treatment O
with O
DOXIL O
and O
up O
to O
6 O
years O
after O
the O
last O
dose O
. O

Examine O
patients O
at O
regular O
intervals O
for O
the O
presence O
of O
oral B-NonOSE_AE
ulceration I-NonOSE_AE
or O
with O
any O
oral B-NonOSE_AE
discomfort I-NonOSE_AE
that O
may O
be O
indicative O
of O
secondary O
oral B-NonOSE_AE
cancer I-NonOSE_AE
. O

The O
altered O
pharmacokinetics O
and O
preferential O
tissue O
distribution O
of O
liposomal O
doxorubicin O
that O
contributes O
to O
enhanced O
skin B-NonOSE_AE
toxicity I-NonOSE_AE
and O
mucositis B-NonOSE_AE
compared O
to O
free O
doxorubicin O
may O
play O
a O
role O
in O
the O
development O
of O
oral B-NonOSE_AE
secondary I-NonOSE_AE
malignancies I-NonOSE_AE
with O
long-term O
use O
. O

5.5 O
Embryofetal B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Based O
on O
animal O
data O
, O
DOXIL O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

At O
doses O
approximately O
0.12 O
times O
the O
recommended O
clinical O
dose O
, O
DOXIL O
was O
embryotoxic B-NonOSE_AE
and O
abortifacient B-NonOSE_AE
in O
rabbits O
. O

Advise O
pregnant B-Not_AE_Candidate
women O
of O
the O
potential O
risk B-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Advise O
females O
and O
males O
of O
reproductive O
potential O
to O
use O
effective O
contraception O
during O
and O
for O
6 O
months O
after O
treatment O
with O
DOXIL O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
and O
( O
8.3 O
) O
] O
. O

